Klaver Yarne, Kunert Andre, Sleijfer Stefan, Debets Reno, Lamers Cor H J
Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
Immunotherapy. 2015;7(5):513-33. doi: 10.2217/imt.15.23.
Cancer immune therapy, in particular the use of checkpoint inhibitors and adoptive transfer of T cells has recently demonstrated significant clinical responses against several tumor types. Unfortunately, these therapies are frequently accompanied by severe toxicities, underscoring the need for markers that provide information on therapy response. Monitoring immune responses in the tumor microenvironment and peripheral blood prior to and during these therapies will provide better insight into the mechanisms underlying clinical activities, and will potentially enable the identification of such markers. In this review, we present an overview of adoptive T-cell trials conducted with a special focus on immune monitoring, and argue that accurate monitoring of T cells is pivotal to further development of immune therapies to treat cancer.
癌症免疫疗法，尤其是检查点抑制剂的使用和T细胞的过继转移，最近已证明对多种肿瘤类型有显著的临床反应。不幸的是，这些疗法常常伴随着严重的毒性，这突出了对能够提供治疗反应信息的标志物的需求。在这些疗法之前和期间监测肿瘤微环境和外周血中的免疫反应，将能更好地洞察临床活性的潜在机制，并有可能识别出此类标志物。在本综述中，我们特别关注免疫监测，概述了过继性T细胞试验，并认为准确监测T细胞对于免疫疗法治疗癌症的进一步发展至关重要。
